Abstract
One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, so that the concept of hormone-dependence can be extended to growth factors deprivation. Hormone deprivation has been therapeutically achieved up to now by surgical, radiation and chemical means. However, the immune system usually can be manipulated to recognize hormones and growth factors, and in fact some autoimmune diseases exists involving autoantibodies against hormones. The idea of inducing a deprivation of hormones and growth factors by active immunizations is appealing, and initial evidence about the feasibility of this approach is starting to appear in the literature. Clinical trials have been initiated using immunization with human chorionic gonadotrophin (hCG), gastrin, luteinizing hormone releasing hormone (LHRH) / gonadotropin releasing hormone (GnRH) and epidermal growth factor (EGF). Preliminary data already show that antibody titers can be elicited, which results in a decrease in the concentration of a given hormone or growth factor. Both the antibody titers and the decrease in the hormone level are related to survival. This immunological approach for hormone and growth factor deprivation creates the possibility of chronic management of advanced cancer patients.
Keywords: Cancer vaccines, immunotherapy, endocrine therapy, hormones, growth factors
Current Cancer Drug Targets
Title: Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Volume: 7 Issue: 3
Author(s): G. Gonzalez and A. Lage
Affiliation:
Keywords: Cancer vaccines, immunotherapy, endocrine therapy, hormones, growth factors
Abstract: One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, so that the concept of hormone-dependence can be extended to growth factors deprivation. Hormone deprivation has been therapeutically achieved up to now by surgical, radiation and chemical means. However, the immune system usually can be manipulated to recognize hormones and growth factors, and in fact some autoimmune diseases exists involving autoantibodies against hormones. The idea of inducing a deprivation of hormones and growth factors by active immunizations is appealing, and initial evidence about the feasibility of this approach is starting to appear in the literature. Clinical trials have been initiated using immunization with human chorionic gonadotrophin (hCG), gastrin, luteinizing hormone releasing hormone (LHRH) / gonadotropin releasing hormone (GnRH) and epidermal growth factor (EGF). Preliminary data already show that antibody titers can be elicited, which results in a decrease in the concentration of a given hormone or growth factor. Both the antibody titers and the decrease in the hormone level are related to survival. This immunological approach for hormone and growth factor deprivation creates the possibility of chronic management of advanced cancer patients.
Export Options
About this article
Cite this article as:
Gonzalez G. and Lage A., Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment, Current Cancer Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/156800907780618310
DOI https://dx.doi.org/10.2174/156800907780618310 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Introduction from Editor-in-Chief
Current Rheumatology Reviews Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthesis and Immunosuppressive Activity of New Mycophenolic Acid Derivatives
Medicinal Chemistry Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Updates on GMSCs Treatment for Autoimmune Diseases
Current Stem Cell Research & Therapy miRNA Functions in Arthritis
Current Rheumatology Reviews Vasculitis Following Influenza Vaccination: A Review of the Literature
Current Rheumatology Reviews Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) Patients’ Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Current Drug Metabolism PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection
Endocrine, Metabolic & Immune Disorders - Drug Targets Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials